Plasma N-terminal Prosomatostatin and Risk of Incident Cardiovascular Disease and All-Cause Mortality in a Prospective Observational Cohort: the PREVEND Study

Ali Abbasi; Lyanne M. Kieneker; Eva Corpeleijn; Ron T. Gansevoort; Rijk O. B. Gans; Joachim Struck; Rudolf A. de Boer; Hans L. Hillege; Ronald P. Stolk; Gerjan Navis; Stephan J. L. Bakker

doi:10.1373/clinchem.2016.259275

Plasma N-terminal Prosomatostatin and Risk of Incident Cardiovascular Disease and All-Cause Mortality in a Prospective Observational Cohort: the PREVEND Study

Ali Abbasi, Lyanne M. Kieneker, Eva Corpeleijn, Ron T. Gansevoort, Rijk O. B. Gans, Joachim Struck, Rudolf A. de Boer, Hans L. Hillege, Ronald P. Stolk, Gerjan Navis, Stephan J. L. Bakker

Research output: Contribution to journal › Article › Academic › peer-review

4 Citations (Scopus)

Abstract

BACKGROUND: Somatostatin is a component of the well-known insulin-like growth factor-1growth hormone (GH) longevity axis. There is observational evidence that increased GH is associated with an increased risk of cardiovascular disease (CVD). We aimed to investigate the potential association of plasma N-terminal fragment prosomatostatin (NT-proSST) with incident CVD and all-cause mortality in apparently healthy adults.METHODS: We studied 8134 participants without history of CVD (aged 28-75 years; women, 52.6%) from the Prevention of Renal and Vascular End-stage Disease (PREVEND) study in Groningen, the Netherlands. Plasma NT-proSST was measured in baseline samples. Outcomes were incidence of CVD and all-cause mortality.RESULTS: In cross-sectional analyses, NT-proSST [mean (SD), 384.0 (169.3) pmol/L] was positively associated with male sex and age (both P

Original language	English
Pages (from-to)	278-287
Number of pages	10
Journal	Clinical Chemistry
Volume	63
Issue number	1
DOIs	https://doi.org/10.1373/clinchem.2016.259275
Publication status	Published - Jan 2017
Externally published	Yes

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1373/clinchem.2016.259275

Cite this

Abbasi, A., Kieneker, L. M., Corpeleijn, E., Gansevoort, R. T., Gans, R. O. B., Struck, J., de Boer, R. A., Hillege, H. L., Stolk, R. P., Navis, G., & Bakker, S. J. L. (2017). Plasma N-terminal Prosomatostatin and Risk of Incident Cardiovascular Disease and All-Cause Mortality in a Prospective Observational Cohort: the PREVEND Study. Clinical Chemistry, 63(1), 278-287. https://doi.org/10.1373/clinchem.2016.259275

@article{c0a44036d6784591ad010fd863171393,

title = "Plasma N-terminal Prosomatostatin and Risk of Incident Cardiovascular Disease and All-Cause Mortality in a Prospective Observational Cohort: the PREVEND Study",

abstract = "BACKGROUND: Somatostatin is a component of the well-known insulin-like growth factor-1growth hormone (GH) longevity axis. There is observational evidence that increased GH is associated with an increased risk of cardiovascular disease (CVD). We aimed to investigate the potential association of plasma N-terminal fragment prosomatostatin (NT-proSST) with incident CVD and all-cause mortality in apparently healthy adults.METHODS: We studied 8134 participants without history of CVD (aged 28-75 years; women, 52.6%) from the Prevention of Renal and Vascular End-stage Disease (PREVEND) study in Groningen, the Netherlands. Plasma NT-proSST was measured in baseline samples. Outcomes were incidence of CVD and all-cause mortality.RESULTS: In cross-sectional analyses, NT-proSST [mean (SD), 384.0 (169.3) pmol/L] was positively associated with male sex and age (both P ",

author = "Ali Abbasi and Kieneker, {Lyanne M.} and Eva Corpeleijn and Gansevoort, {Ron T.} and Gans, {Rijk O. B.} and Joachim Struck and {de Boer}, {Rudolf A.} and Hillege, {Hans L.} and Stolk, {Ronald P.} and Gerjan Navis and Bakker, {Stephan J. L.}",

note = "{\textcopyright} 2016 American Association for Clinical Chemistry.",

year = "2017",

month = jan,

doi = "10.1373/clinchem.2016.259275",

language = "English",

volume = "63",

pages = "278--287",

journal = "Clinical Chemistry",

issn = "0009-9147",

publisher = "American Association for Clinical Chemistry Inc.",

number = "1",

}

Abbasi, A, Kieneker, LM, Corpeleijn, E, Gansevoort, RT, Gans, ROB, Struck, J, de Boer, RA, Hillege, HL, Stolk, RP, Navis, G & Bakker, SJL 2017, 'Plasma N-terminal Prosomatostatin and Risk of Incident Cardiovascular Disease and All-Cause Mortality in a Prospective Observational Cohort: the PREVEND Study', Clinical Chemistry, vol. 63, no. 1, pp. 278-287. https://doi.org/10.1373/clinchem.2016.259275

TY - JOUR

T1 - Plasma N-terminal Prosomatostatin and Risk of Incident Cardiovascular Disease and All-Cause Mortality in a Prospective Observational Cohort

T2 - the PREVEND Study

AU - Abbasi, Ali

AU - Kieneker, Lyanne M.

AU - Corpeleijn, Eva

AU - Gansevoort, Ron T.

AU - Gans, Rijk O. B.

AU - Struck, Joachim

AU - de Boer, Rudolf A.

AU - Hillege, Hans L.

AU - Stolk, Ronald P.

AU - Navis, Gerjan

AU - Bakker, Stephan J. L.

PY - 2017/1

Y1 - 2017/1

N2 - BACKGROUND: Somatostatin is a component of the well-known insulin-like growth factor-1growth hormone (GH) longevity axis. There is observational evidence that increased GH is associated with an increased risk of cardiovascular disease (CVD). We aimed to investigate the potential association of plasma N-terminal fragment prosomatostatin (NT-proSST) with incident CVD and all-cause mortality in apparently healthy adults.METHODS: We studied 8134 participants without history of CVD (aged 28-75 years; women, 52.6%) from the Prevention of Renal and Vascular End-stage Disease (PREVEND) study in Groningen, the Netherlands. Plasma NT-proSST was measured in baseline samples. Outcomes were incidence of CVD and all-cause mortality.RESULTS: In cross-sectional analyses, NT-proSST [mean (SD), 384.0 (169.3) pmol/L] was positively associated with male sex and age (both P

AB - BACKGROUND: Somatostatin is a component of the well-known insulin-like growth factor-1growth hormone (GH) longevity axis. There is observational evidence that increased GH is associated with an increased risk of cardiovascular disease (CVD). We aimed to investigate the potential association of plasma N-terminal fragment prosomatostatin (NT-proSST) with incident CVD and all-cause mortality in apparently healthy adults.METHODS: We studied 8134 participants without history of CVD (aged 28-75 years; women, 52.6%) from the Prevention of Renal and Vascular End-stage Disease (PREVEND) study in Groningen, the Netherlands. Plasma NT-proSST was measured in baseline samples. Outcomes were incidence of CVD and all-cause mortality.RESULTS: In cross-sectional analyses, NT-proSST [mean (SD), 384.0 (169.3) pmol/L] was positively associated with male sex and age (both P

U2 - 10.1373/clinchem.2016.259275

DO - 10.1373/clinchem.2016.259275

M3 - Article

SN - 0009-9147

VL - 63

SP - 278

EP - 287

JO - Clinical Chemistry

JF - Clinical Chemistry

IS - 1

ER -

Plasma N-terminal Prosomatostatin and Risk of Incident Cardiovascular Disease and All-Cause Mortality in a Prospective Observational Cohort: the PREVEND Study

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Cite this